{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:05:59Z","timestamp":1782536759217,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jconrel.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T13:11:12Z","timestamp":1731157872000},"page":"1130-1142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"376","author":[{"given":"Yapeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoju","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunliang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.11.006_bb0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0030","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2023.01.039","article-title":"Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease","volume":"355","author":"Chikamatsu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0040","doi-asserted-by":"crossref","first-page":"eaaz9890","DOI":"10.1126\/sciadv.aaz9890","article-title":"Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia","volume":"6","author":"Gilroy","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/bc300603k","article-title":"Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation","volume":"24","author":"Xu","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0050","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bph.13499","article-title":"Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity","volume":"173","author":"Yin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2018.03.015","article-title":"Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action","volume":"277","author":"Gilroy","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0060","article-title":"Atomically accurate de novo design of single-domain antibodies","author":"Bennett","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41586-023-05909-9","article-title":"De novo design of modular peptide-binding proteins by superhelical matching","volume":"616","author":"Wu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0070","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.abf4896","article-title":"Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets","volume":"371","author":"de Vries","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0075","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acs.bioconjchem.2c00034","article-title":"Dimerization of the peptide CXCR4-antagonist on macromolecular and supramolecular protraction arms affords increased potency and enhanced plasma stability","volume":"33","author":"Harms","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.seminhematol.2014.10.007","article-title":"Development of romiplostim: a novel engineered peptibody","volume":"52","author":"Yang","year":"2015","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0090","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1021\/acs.jmedchem.2c01021","article-title":"Non-covalent albumin ligands in FDA-approved therapeutic peptides and proteins","volume":"66","author":"Zaragoza","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.actbio.2023.09.018","article-title":"Engineered therapeutic proteins for sustained-release drug delivery systems","volume":"171","author":"Nguyen","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0105","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0110","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0115","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1021\/acs.jmedchem.1c02039","article-title":"Molecular engineering of efficacious mono-valent ultra-long acting two-chain insulin-fc conjugates","volume":"65","author":"Tagmose","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0120","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-klotho, and enhanced efficacy in mice and Cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2020.01.034","article-title":"Intramolecular distance in the conjugate of urate oxidase and fatty acid governs FcRn binding and serum half-life in vivo","volume":"321","author":"Cho","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0140","doi-asserted-by":"crossref","first-page":"21763","DOI":"10.1021\/jacs.2c10194","article-title":"Generation of proteins with free N-terminal cysteine by aminopeptidases","volume":"144","author":"Hempfling","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0145","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.bioconjchem.8b00463","article-title":"Long-acting human growth hormone analogue by noncovalent albumin binding","volume":"29","author":"Ramirez-Andersen","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0150","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1021\/acs.biochem.0c00019","article-title":"Identification of binding sites on human serum albumin for Somapacitan, a long-acting growth hormone derivative","volume":"59","author":"Johansson","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0155","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jgh.14122","article-title":"Mouse models of non-alcoholic steatohepatitis: a reflection on recent literature","volume":"33","author":"Haczeyni","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12944-020-01419-z","article-title":"Association between the alanine aminotransferase\/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study","volume":"19","author":"Zou","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175811","article-title":"Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis","volume":"952","author":"Ye","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0175","first-page":"1080","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial, lancet","volume":"8","author":"Harrison","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2024.11.006_bb0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2024.11.006_bb0185","doi-asserted-by":"crossref","first-page":"2171248","DOI":"10.1080\/19420862.2023.2171248","article-title":"Assessing developability early in the discovery process for novel biologics","volume":"15","author":"Fernandez-Quintero","year":"2023","journal-title":"MAbs"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400751X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400751X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:39:00Z","timestamp":1733578740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592400751X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S016836592400751X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}